Decoding male breast cancer: epidemiological insights, cutting-edge treatments, and future perspectives.

IF 2.8 4区 医学 Q3 ENDOCRINOLOGY & METABOLISM Discover. Oncology Pub Date : 2025-03-19 DOI:10.1007/s12672-025-02140-y
Lei Zhao, Huijuan Cheng, Dongqiang He, Yalan Zhang, Yahui Chai, Ailin Song, Guodong Sun
{"title":"Decoding male breast cancer: epidemiological insights, cutting-edge treatments, and future perspectives.","authors":"Lei Zhao, Huijuan Cheng, Dongqiang He, Yalan Zhang, Yahui Chai, Ailin Song, Guodong Sun","doi":"10.1007/s12672-025-02140-y","DOIUrl":null,"url":null,"abstract":"<p><p>Breast cancer is predominantly recognized as a condition affecting women, however, male breast cancer (MBC), despite its rarity, represents a significant and serious malignancy in men. Accounting for approximately 1% of all breast cancer cases, MBC is often diagnosed at a later stage compared to female breast cancer, primarily due to a lack of awareness and the absence of screening programs tailored for men. This delayed diagnosis typically results in poorer prognoses and more limited treatment options. Over the past decade, there has been a notable increase in research and awareness surrounding MBC. This surge is largely driven by the recognition of its unique epidemiological and biological characteristics, which are distinct from those of female breast cancer. However, due to its low incidence, many aspects of MBC, including its etiology, clinical presentation, and optimal treatment strategies, remain inadequately understood. This paper aims to provide a comprehensive review of MBC by examining its incidence, mortality rates, and epidemiological characteristics on a global scale. Additionally, it explores the economic burden associated with the disease, identifies key risk factors, and discusses current preventive measures. Finally, the paper will offer insights into future research directions and potential advancements in the diagnosis and treatment of MBC.</p>","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"360"},"PeriodicalIF":2.8000,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Discover. Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12672-025-02140-y","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Breast cancer is predominantly recognized as a condition affecting women, however, male breast cancer (MBC), despite its rarity, represents a significant and serious malignancy in men. Accounting for approximately 1% of all breast cancer cases, MBC is often diagnosed at a later stage compared to female breast cancer, primarily due to a lack of awareness and the absence of screening programs tailored for men. This delayed diagnosis typically results in poorer prognoses and more limited treatment options. Over the past decade, there has been a notable increase in research and awareness surrounding MBC. This surge is largely driven by the recognition of its unique epidemiological and biological characteristics, which are distinct from those of female breast cancer. However, due to its low incidence, many aspects of MBC, including its etiology, clinical presentation, and optimal treatment strategies, remain inadequately understood. This paper aims to provide a comprehensive review of MBC by examining its incidence, mortality rates, and epidemiological characteristics on a global scale. Additionally, it explores the economic burden associated with the disease, identifies key risk factors, and discusses current preventive measures. Finally, the paper will offer insights into future research directions and potential advancements in the diagnosis and treatment of MBC.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
求助全文
约1分钟内获得全文 去求助
来源期刊
Discover. Oncology
Discover. Oncology Medicine-Endocrinology, Diabetes and Metabolism
CiteScore
2.40
自引率
9.10%
发文量
122
审稿时长
5 weeks
期刊最新文献
Classification of lung adenocarcinoma based on senescence-related genes identifies a cluster with immunotherapy resistance and poor prognosis. Expression and prognosis of NR3C1 in uterine corpus endometrial carcinoma based on multiple datasets. Microplastics: a cancer-causing agent for humans and prospects for identification using AI and modern approaches. PRSS53 is a potential novel biomarker related to prognosis and immunity in clear cell renal cell carcinoma. Tanshinone IIA affects the proliferation of A549/Tax by affecting the expression of MMP7 through the PI3K-AKT-mTOR signaling pathway.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1